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Background and purpose —  It is still being debated whether HA 
coating of uncemented stems used in total hip arthroplasty (THA) 
improves implant survival. We therefore investigated different 
uncemented stem brands, with and without HA coating, regard-
ing early and long-term survival.
Patients and methods — We identified 152,410 THA procedures 
using uncemented stems that were performed between 1995 and 
2011 and registered in the Nordic Arthroplasty Register Associa-
tion (NARA) database. We excluded 19,446 procedures that used 
stem brands less than 500 times in each country, procedures per-
formed due to diagnoses other than osteoarthritis or pediatric hip 
disease, and procedures with missing information on the type of 
coating. 22 stem brands remained (which were used in 116,069 
procedures) for analysis of revision of any component. 79,192 pro-
cedures from Denmark, Norway, and Sweden were analyzed for 
the endpoint stem revision. Unadjusted survival rates were calcu-
lated according to Kaplan-Meier, and Cox proportional hazards 
models were fitted in order to calculate hazard ratios (HRs) for 
the risk of revision with 95% confidence intervals (CIs).
Results — Unadjusted 10-year survival with the endpoint revi-
sion of any component for any reason was 92.1% (CI: 91.8–92.4). 
Unadjusted 10-year survival with the endpoint stem revision due 
to aseptic loosening varied between the stem brands investigated 
and ranged from 96.7% (CI: 94.4–99.0) to 99.9% (CI: 99.6–100). 
Of the stem brands with the best survival, stems with and with-
out HA coating were found. The presence of HA coating was not 
associated with statistically significant effects on the adjusted risk 
of stem revision due to aseptic loosening, with an HR of 0.8 (CI: 
0.5–1.3; p = 0.4). The adjusted risk of revision due to infection 
was similar in the groups of THAs using HA-coated and non-
HA-coated stems, with an HR of 0.9 (CI: 0.8–1.1; p = 0.6) for the 
presence of HA coating. The commonly used Bimetric stem (n = 
25,329) was available both with and without HA coating, and the 
adjusted risk of stem revision due to aseptic loosening was similar 
for the 2 variants, with an HR of 0.9 (CI: 0.5–1.4; p = 0.5) for the 
HA-coated Bimetric stem.
Interpretation — Uncemented HA-coated stems had similar 
results to those of uncemented stems with porous coating or rough 
sand-blasted stems. The use of HA coating on stems available both 
with and without this surface treatment had no clinically relevant 
effect on their outcome, and we thus question whether HA coating 
adds any value to well-functioning stem designs.

Hydroxyapatite (HA) is thought to improve early implant 
ingrowth and long-term stability in bone (Overgaard et al. 
1997), and many stems intended for uncemented total hip 
arthroplasty (THA) are thus manufactured with HA coating. 
Several uncemented stems are only available with HA coating. 
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Some HA-coated stems have excellent long-term outcomes in 
terms of the risk of revision, both for any reason and due to 
aseptic loosening (Capello et al. 2003, Shah et al. 2009). Reg-
istry data from Norway and Finland also indicate that certain 
HA-coated stems have excellent survivorship up to 10 years 
(Eskelinen et al. 2006, Hallan et al. 2007, Makela et al. 2008).
On the other hand, a number of studies on stem survival in 
the setting of randomized trials or smaller observational stud-
ies have failed to show beneficial effects of HA coating on 
clinical outcome and implant survival when compared to alter-
natives such as porous coating and sand-blasted rough surfaces 
(McPherson et al. 1995, Tanzer et al. 2001, Kim et al. 2003, 
Parvizi et al. 2004, Sanchez-Sotelo et al. 2004). Meta-analyses 
that have pooled data from randomized or cohort studies have 
come to the conclusion that there is “[…] no clinically ben-
eficial effect to the addition of HA to porous coating alone 
in primary uncemented hip arthroplasty” (Gandhi et al. 2009, 
Li et al. 2013). In addition, a Danish registry analysis found 
that the use of HA coating does not reduce the risk of stem 
revision (Paulsen et al. 2007). Furthermore, a comparison of 
4,772 uncemented Bimetric stems with or without HA coating 
implanted between 1992 and 2009 did not reveal any differ-
ence in survival between the 2 variants (Lazarinis et al. 2011).
HA was initially introduced as an implant coating to speed 
up and facilitate ongrowth and ingrowth of bone and thereby 
improve fixation, based on comprehensive preclinical and 
promising clinical documentation (Geesink et al. 1987, Bauer 
et al. 1991, Overgaard et al. 1997, Karrholm et al. 1998). Later 
on, concerns were raised due to findings of delamination and 
generation of HA particles originating from the coating with 
the potential to trigger osteolysis, acceleration of polyethyl-
ene wear, and subsequent implant loosening (Bloebaum and 
Dupont 1993, Morscher et al. 1998, Lazarinis et al. 2010). 
Today, there is renewed interest in HA coatings due to pos-
sible properties as a carrier for agents aimed at preventing 
infection (Ghani et al. 2012). Theoretical arguments for and 
against the use of HA coating can therefore be found. Given 
the renewed interest in uncemented stems—instigated by 
favorable outcomes after uncemented stem fixation in younger 
patients—the question of whether HA coating is beneficial or 
not is highly relevant (Eskelinen et al. 2006, Hooper et al. 
2009, Swedish Hip Arthroplasty Register 2011). We therefore 
investigated uncemented stems with and without HA coat-
ing that are in frequent use in the Nordic countries, regarding 
early and long-term survival.
Patients and methods
Source of data
The Nordic Arthroplasty Register Association (NARA) data-
set originally contained merged individual-based data from 
the Danish, Norwegian, and Swedish arthroplasty registries 
(Havelin et al. 2009), and Finland recently joined this col-
laboration (Havelin et al. 2011). Data from each contributing 
registry were transformed into a common dataset following a 
predetermined set of definitions, and all revisions were linked 
to the primary procedures. Prior to the merging of the national 
datasets, they were de-identified by deletion of personal iden-
tification numbers, and the common dataset was then pro-
cessed in compliance with the national regulations governing 
research on registry data in each participating country.
Terminology
The term “revision” was defined as a new operation where 
1 or more components of the primary THA prosthesis were 
exchanged, or where the entire prosthesis or parts of it were 
removed. Other types of reoperations where all implant parts 
were left in situ, e.g. closed reductions or incision and drain-
age, were not available from NARA data. Revisions were 
grouped further into revisions for any reason and revisions 
for specific reasons including aseptic loosening, infection, or 
periprosthetic fracture. Finally, in the subgroup of procedures 
performed in Denmark, Norway, or Sweden, detailed informa-
tion on the procedures performed during revision surgery was 
available, enabling the analysis of stem revisions for specific 
reasons.
Diagnosis at index surgery was categorized into primary 
osteoarthritis (OA) or previous pediatric hip disease (defined 
as developmental dysplasia of the hip, Perthes’ disease, or 
slipped femoral epiphysis), whereas procedures performed 
due to femoral neck fractures, inflammatory joint disease, 
and other diagnoses were excluded (see “Characteristics of 
the study population”). Age at the time of the index procedure 
was categorized into the age groups < 50, 50–59, 60–74, and 
≥ 75 years.
Statistics
We adhered to the guidelines on the statistical analysis of 
registry data (Ranstam et al. 2011). Continuous data are 
described using means, medians, and ranges. 95% confidence 
intervals (CIs) are used to describe estimation uncertainty. 
Categorical data were summarized in cross tables and the 
chi-square test was used to investigate whether observed and 
expected frequencies differed significantly between groups of 
data. Follow-up started on the day of primary THA and ended 
on the day of revision, death, emigration, or December 31, 
2011, whichever came first. Kaplan-Meier survival analysis 
was performed to calculate cumulative unadjusted component 
survival functions, with revision of any component or revision 
of the stem for any of the reasons given above as the endpoint. 
The log-rank test (Mantel-Cox) was used to investigate differ-
ences between groups. In order to calculate crude and adjusted 
hazard ratios (HRs) for relevant covariates, Cox regression 
models were fitted using the Efron method for handling ties. 
The risk of early revision for various reasons was investigated 
by calculating the risk of revision during the first 6 postopera-
tive months only. Separate models were fitted for the covari-
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ates HA coating, age, sex, diagnosis, and country of residence 
in order to calculate crude HRs with CI, and certain covari-
ates were subsequently entered into Cox multiple regres-
sion models to enable calculation of adjusted HRs. In order 
to decide what covariates should be included in the models, 
directed acyclic graphs of possible causal relations were used 
(Shrier and Platt 2008). Model assumptions were investigated 
by calculating and plotting the correlation coefficient between 
transformed survival time and the scaled Schoenfeld residu-
als. When covariates did not meet model assumptions but 
were deemed to be relevant to outcome, adjusted multivari-
able models were fitted, stratified for these covariates (e.g. 
brand of stem). The level of significance was set at p < 0.05 in 
all analyses. We used R software version 3.0.2, including the 
“rms” and “Gmisc” packages (Harrell 2012, R Development 
Core Team 2012, Gordon 2013).
The analysis of both joints in bilaterally operated patients 
does not appear to lead to bias in registry studies of this size, 
and these were therefore included in the analysis (Robertsson 
and Ranstam 2003, Lie et al. 2004, Hailer et al. 2010). 22,069 
of the 152,410 procedures eligible for the analyses presented 
here (15%) were based on bilateral observations.
Characteristics of the study population
Data on primary THA procedures using uncemented stems 
performed from 1995 through 2011 were pooled: 46,499 from 
Denmark, 27,748 from Norway, 28,244 from Sweden, and 
49,919 from Finland, resulting in 152,410 procedures that were 
eligible for analysis. To reduce the influence of stem designs 
used in small numbers, we excluded all procedures involving 
a stem brand that had been used less than 500 times in each 
country. This left a total number of 135,515 THA procedures 
involving 22 different stem brands. We also excluded 19,446 
THA procedures performed due to diagnoses other than osteo-
arthritis or pediatric hip disease, and those with erroneous or 
ambiguous information on the presence of HA coating. This 
left 116,069 THAs for the final analysis (Table 1).
The 116,069 procedures that were available for final analy-
sis had been performed in 300 units. 94,309 stems were com-
bined with uncemented cups, creating totally uncemented 
THA, 21,760 stems were combined with cemented cups, cre-
ating reversed hybrid THA. The number of cup brands was 
large, with more than 100 brands represented in the database. 
The 22 stem brands included in the analyses were categorized 
according to whether or not they had HA coating; 57,255 were 
not HA-coated and 58,814 were (Table 2).
Women were over-represented in the group of HA-coated 
stems (p < 0.001 for chi-square overall) (Table 3). Procedures 
performed in patients younger or older than the reference 
group (60–74 years) were over-represented in the group of 
HA-coated stems (p < 0.001 for chi-square overall) (Table 3). 
Procedures performed due to pediatric hip disease were more 
commonly performed using HA-coated stems (p < 0.001 for 
chi-square overall) (Table 3). The sex distributions and distri-
Table 1. Procedures sorted according to stem brand in each coun-
try, after exclusion of stem brands used in less than 500 cases per 
country, and after exclusion of all diagnoses other than osteoarthri-
tis or pediatric hip disease
 Denmark Norway Sweden Finland Total
Total 35,513 20,850 22,829 36,877 116,069
Bimetric 20,192 0 5,137 17,402 42,731
Corail 7,067 14,581 5,125 1,454 28,227
CLS 2,218 0 7,569 0 9,787
ABG 0 499 3,010 5,363 8,872
Synergy 714 0 0 2,564 3,278
Summit 0 0 0 3,166 3,166
Accolade 0 0 1,157 1,817 2,974
Filler 0 2,328 0 0 2,328
ML-Taper 0 0 0 2,214 2,214
Bicontact 1,580 0 0 0 1,580
Profemur 407 0 0 893 1,300
Anca-Fit 1,100 0 0 0 1,100
Omnifit 0 686 0 398 1,084
SCP 0 1,073 0 0 1,073
Hactiv 0 1,023 0 0 1,023
Symax 962 0 0 0 962
Anthology 0 0 0 898 898
Cone 0 0 831 0 831
Taperloc 0 0 0 708 708
Zweymuller 0 660 0 0 660
Versys 659 0 0 0 659
AML 614 0 0 0 614
Stem brands are ordered by total number in descending order.
Table 2. Presence or absence of HA coating on the 22 
stem brands included
 no HA HA
 coating coating Total
Total 57,255 58,814 116,069
Bimetric 31,768 10,963 42,731
Corail 0 28,227 28,227
CLS 9,741 46 9,787
ABG 0 8,872 8,872
Synergy 3,278 0 3,278
Summit 3,166 0 3,166
Accolade 0 2,974 2,974
Filler 243 2,085 2,328
ML-Taper 2,214 0 2,214
Bicontact 1,580 0 1,580
Profemur 895 405 1,300
Anca-Fit 0 1,100 1,100
Omnifit 0 1,084 1,084
SCP 0 1,073 1,073
Hactiv 0 1,023 1,023
Symax 0 962 962
Anthology 898 0 898
Cone 831 0 831
Taperloc 708 0 708
Zweymuller 660 0 660
Versys 659 0 659
AML 614 0 614
Stems are ordered by total number in descending order. 
There were no missing data on HA coating.
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butions of diagnoses and age groups in the participating coun-
tries are given in Supplementary Table 4.
The risk of stem revision for various reasons was inves-
tigated in the subgroup of THAs performed in Denmark, 
Norway, and Sweden since the procedure “stem revision due 
to aseptic loosening” is not yet uniformly registered in Fin-
land. This subgroup involved 79,192 procedures using 18 dif-
ferent brands of stem.
Results
Risk of revision of any component
The median observation time for the 116,069 THAs with the 22 
selected uncemented stem brands was 3.6 (0–17) years. In this 
cohort, 5,223 THAs (4.5%) were revised with exchange of any 
component for any reason during the observation period. 1,631 
revisions (1.4%) were done due to aseptic loosening of stem or 
cup or both, 629 (0.5%) were done due to infection, and 572 
(0.5%) were done due to periprosthetic femoral fracture.
Unadjusted 10-year survival was 92.1% (CI: 91.8–92.4) 
with revision of any component for any reason as the end-
point. We then dichotomized the selected THAs into those 
using HA-coated stems and those using non-HA-coated 
stems. Unadjusted 10-year survival with the endpoint revision 
of any component for any reason was 92% (CI: 91.7–92.4) for 
the group of THAs without HA-coated stems (number at risk 
after 10 years: 6,676) and it was 92.1% (CI: 91.7–92.5) for 
those with HA-coated stems (number at risk after 10 years: 
6,464) (p = 0.3).
Unadjusted 10-year survival due to infection was 99.3% 
(CI: 99.2–99.4) for all investigated THAs using stems without 
HA coating and it was 99.2% (CI: 99.0–99.3) for those using 
stems with HA coating (p = 0.002). After adjusting for age, 
sex, diagnosis, and country of residence as strata variables, 
we found that there was no statistically significant difference 
in the adjusted risk of revision due to infection between the 
group of THAs with HA-coated stems and that with non-HA-
coated stems, with an HR of 0.9 (CI: 0.8–1.1) for the presence 
of HA coating versus non-HA coating (p = 0.6).
Risk of stem revision for various reasons
Median observation time for the subgroup of THAs performed 
in Denmark, Norway, and Sweden was 3.2 (0–17) years, 
which was therefore quite similar to the observation time for 
the entire study population. In this subgroup, 3,018 (3.8%) 
of all primary THAs underwent a revision procedure. 1,106 
(1.4%) were stem revisions for any reason, and 273 (0.3%) 
were stem revisions performed because of aseptic loosening.
The unadjusted 10-year survival for this subgroup, with 
the endpoint revision of any component for any reason, was 
92.8% (CI: 92.5–93.2). With the endpoint stem revision for 
any reason, it was 97.8% (CI: 97.6–98.0), and with the end-
point stem revision due to aseptic loosening, it was 99.3% (CI: 
99.2–99.4). Unadjusted 10-year survival of non-HA-coated 
stems with the endpoint stem revision for any reason was 
98.0% (CI: 97.7–98.2), and the corresponding survival rate 
for HA-coated stems was 97.7% (CI: 97.4–97.9) (p = 0.7). 
Unadjusted 10-year survival of non-HA-coated stems with the 
endpoint stem revision due to aseptic loosening was 99.4% 
(CI: 99.2–99.5), and the survival rate for HA-coated stems 
with the same endpoint was 99.3% (CI: 99.1–99.4) (p = 0.6). 
The numbers at risk at this time point were 2,503 for the non-
HA-coated stems and 4,042 for the HA-coated stems.
Unadjusted 10-year stem survival with the endpoint revi-
sion due to aseptic loosening for the 11 stem brands that 
were available for 10-year analysis in the Danish-Norwegian-
Table 3. Sex-, diagnosis-, and age distribution accord-
ing to whether or not the stem had HA coating
 No HA coating HA coating
 n % n %
Male 28,277 49 25,928 44
Female 28,978 51 32,886 56
Sum 57,255 100 58,814 100
OA 54,520 95 52,965 90
Pediatric 2,735 5 5,849 10
Sum 57,255 100 58,814 100
< 50 5,218 9 5,986 10
50–59 15,760 28 15,385 26
60–74 30,591 53 29,737 51
≥ 75 5,686 10 7,706 13
Total 57,255 100 58,814 100
Figure 1. Unadjusted 10-year survival (with 95% CI) of the stem brands 
used in the Danish-Norwegian-Swedish subgroup, with stem revision 
for aseptic loosening as the endpoint. The 7 stem brands used in the 
Danish-Norwegian-Swedish subgroup that were not included in this 
analysis had fewer than 25 hips at risk after 10 years, and were there-
fore excluded. Stems are ordered by survival estimates, in descending 
order.
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Swedish subgroup is summarized in Figure 1 and in Supple-
mentary Table 5. The 7 stem brands not included in this ana-
lysis had fewer than 25 hips at risk after 10 years, and they 
were therefore excluded. Both HA-coated and non-HA-coated 
stems were represented among the stems with the best 10-year 
survival. 10-year survival analyses stratified by age did not 
indicate that any age group benefited from having received 
HA-coated stems (Supplementary Table 6).
The endpoint stem revision for any reason was further 
investigated by fitting a multivariable Cox regression model 
including the covariates HA coating, age, sex, and diagnosis. 
Proportionality of hazards was not fulfilled for the covariate 
“stem brand” (e.g. Corail, Bimetric, Cone), and the regression 
model was thus stratified by this covariate. The presence of HA 
coating was not associated with statistically significant effects 
on the risk of stem revision for any reason in this regression 
model, with an HR of 1.0 (CI: 0.8–1.2) for HA-coated stems 
vs. non-HA-coated stems (p = 0.8).
The risk of stem revision for any reason within the first 6 
months was investigated separately by fitting a multivariable 
model based on the covariates HA coating, age, and sex, strati-
fied by diagnosis and stem brand. The presence of HA coating 
was not associated with statistically significant effects on the 
risk of stem revision for any reason within the first 6 months, 
with an HR of 0.9 (CI: 0.7–1.2) for HA-coated stems vs. non-
HA-coated stems (p = 0.45).
Then a multivariable Cox regression model was fitted to cal-
culate the adjusted risk of stem revision due to aseptic loosen-
ing. The regression model was again stratified for the covari-
ate “stem brand”. The presence of HA coating had no statisti-
cally significant effects on the adjusted risk of stem revision 
for aseptic loosening, with an HR of 0.8 (CI: 0.5–1.3) for HA-
coated stems vs. non-HA-coated stems (p = 0.4).
Effects of HA coating on a commonly used stem
4 stem brands that had been used in the study population were 
available both with and without HA coating: the Bimetric, Pro-
femur, Filler, and CLS stems. We investigated whether crude 
and adjusted stem survival differed for identical implants that 
were available with or without HA coating. In order to avoid 
bias created by small subgroups, we focused this specific 
analysis on the Bimetric stem, which was by far the most fre-
quently used stem available both with and without HA coat-
ing (Table 1). We excluded Bimetric stems inserted in Finland 
because detailed information on stem revisions due to asep-
tic loosening was unavailable in that part of the cohort. This 
resulted in 25,321 Bimetric stems inserted either in Denmark 
or Sweden for final analysis (the Bimetric stem had not been 
used in Norway). Among these, 371 stems (1.5%) had been 
revised for any reason, and 74 stems (0.3%) had been revised 
due to aseptic loosening.
The unadjusted 10-year survival for the Bimetric stem 
with stem revision for any reason was 98.1 (CI: 97.9–98.4) 
for the non-HA-coated stem and 98.1 (CI: 97.7–98.5) for the 
HA-coated stem (p = 0.6). The adjusted revision risk for HA-
coated Bimetric stems was similar to that for non-HA-coated 
stems, with an HR of 1.0 (CI: 0.8–1.2) for the HA-coated vs. 
the non-HA-coated Bimetric stem when considering the end-
point stem revision for any reason (p = 0.9).
With stem revision due to aseptic loosening as the end-
point, the unadjusted 10-year survival rates were 99.6 (CI: 
99.4–99.7) for the non-HA-coated Bimetric stem and 99.7 
(CI: 99.5–99.8) for the HA-coated stem (p = 0.4). We found 
that HA-coated Bimetric stems had an adjusted risk of revi-
sion due to aseptic loosening that was similar to that for non-
HA-coated stems, with an HR of 0.9 (CI: 0.5–1.4; p = 0.5) 
(Figure 2).
discussion
Is it the form or the finish?
We found no clinically relevant influence of HA coating on 
the risk of stem revision in our large material. This contrasts 
with the widely held belief that HA coating improves early 
stem fixation by faster bone ongrowth and—in the longer 
term—sealing of the effective joint space by bone ingrowth. 
A number of experimental studies on the ingrowth or stability 
of various implants in bone did indeed indicate that HA might 
be beneficial (Soballe et al. 1990, 1993a). The concept of HA 
coating of stems intended for uncemented THA gained addi-
tional support from (1) radiostereometric measurements of fix-
ation showing reduced early migration of HA-coated implants 
(Soballe et al. 1993b), (2) a randomized study indicating that 
HA-coated stems were less prone to periprosthetic bone loss 
Figure 2. Survival of non-HA-coated and HA-coated Bimetric stems for 
females aged 60–74 with a diagnosis of osteoarthritis, with the end-
point stem revision for aseptic loosening in an adjusted Cox regression 
model.
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(Tanzer et al. 2001), and (3) studies indicating improved bone 
remodeling around HA-coated implants (Dorr et al. 1998). 
However, the ultimate goal for HA-coated implants is the 
reduction of loosening of implants and thereby reduced revi-
sions rates. The use of HA coating has not remained unop-
posed, since several studies (both observational and random-
ized) have found no advantage of HA-coated stems over stems 
with other coatings in terms of long-term survival (McPherson 
et al. 1995, Tanzer et al. 2001, Kim et al. 2003, Parvizi et al. 
2004, Sanchez-Sotelo et al. 2004, Lazarinis et al. 2011). The 
drawback in some of these studies was the fact that the conclu-
sions were based on outdated stem designs that were no longer 
in current use (Kärrholm et al. 1998).
We considered revision of any component for any reason 
and revision due to infection—and stem revision for any 
reason and stem revision due to aseptic loosening. The end-
points based on revision of any component were relevant, 
since delamination of HA from stems could have had a nega-
tive influence on cup survival, and the presence of HA coating 
on stems could hypothetically also have influenced the risk of 
infection. It is also reasonable to suspect that stems that were 
mated with poorly performing cups would suffer from this; 
patients who were revised because of a cup problem would be 
more likely to have their stem revised during the same revision 
procedure, either in order to facilitate cup removal or because 
the surgeon could identify a subclinical stem problem such as 
loosening or osteolysis during the revision procedure. Thus, a 
poor cup could have a negative effect on the stem results, so 
we studied the additional endpoints based on stem revisions 
in more detail. We also considered the endpoints stem revi-
sion due to aseptic loosening and stem revision for any reason 
(including the risk of revision within the first 6 months), since 
a failure to osseointegrate might have caused early revisions 
due to periprosthetic fracture.
The best-performing femoral implants included double-
tapered designs such as the Bimetric stem and a tapered design 
with a circular cross section, as represented by the Wagner 
Cone stem. These observations are in accordance with pre-
vious investigations (Strom et al. 2006, Makela et al. 2008). 
The Zweymüller stem with its straight, tapered, rectangular 
cross-sectional design, the Omnifit stem, which is straight 
and tapered, and the ABG with its anatomical design and its 
smooth, sand-blasted surface had 10-year survival rates well 
above 90%, but all performed worse than the stems mentioned 
above. Again, this is in line with previous reports on the sur-
vival of these stems (Hallan et al. 2007). 
The Bimetric stem was the most commonly inserted unce-
mented stem. This tapered titanium stem was associated with 
an excellent crude and adjusted 10-year survival, both consid-
ering stem revisions for any reason and those that were due to 
aseptic loosening. This finding is in line with previous reports 
(Davies et al. 2010), and revisions of THAs using the Bimetric 
stem are frequently associated with failure of the cup but not 
the stem component (Isaac et al. 2007). Low revision rates 
of the Bimetric stem have also been described in a Finnish 
registry study (Eskelinen et al. 2006). However, in a previous 
Swedish registry study, HA coating of Bimetric stems was not 
found to be associated with statistically significant effects on 
stem survival for any reason or due to aseptic loosening, which 
is in line with the present findings (Lazarinis et al. 2011).
Only the Bimetric stem had sufficient numbers of pro-
cedures done with and without HA coating, and the type of 
coating did not affect the fixation of this particular stem. We 
cannot, however, deduce from this finding that the coating had 
no effect on fixation of the other stems; some stem designs 
that had an HA coating could have had poorer or better results 
had the coating been removed from the implant, and implants 
with no HA coating could have performed differently with the 
addition of an HA coating. Moreover, not all HA-coated stems 
are similar, since the surface roughness and the thickness and 
crystallinity of the HA layer vary.
Thus, different design philosophies can successfully be 
applied to uncemented hip stem concepts, but seemingly 
minor differences in stem design and HA coating interact in 
a partially unknown way, which may influence the outcome. 
Lack of osseointegration of uncemented stems can increase 
the risk of early periprosthetic fracture and the risk of early 
loosening, and both of these phenomena—at least in part—
would explain the decrease in cumulative survival of THAs 
during the first postoperative year. Periprosthetic fractures and 
early loosening are also reasons for cemented THAs doing 
better overall than uncemented THAs (Hailer et al. 2010, 
Makela et al. 2014).
Other risk factors for revision
Other factors with a possible influence on outcome were inves-
tigated in exploratory analyses. Analyses that were stratified by 
age group did not indicate that any group fared better or worse 
after having received HA-coated stems (Supplementary Table 
6), and the same was true for women and men (data not shown). 
Inclusion of the type of cup fixation (cemented or uncemented) 
or the type of polyethylene (conventional or highly cross-
linked) did not influence parameter estimates notably (data not 
shown), but this type of information was not available for the 
entire study population, and these exploratory findings must 
therefore be regarded with caution. Some other confounders 
that are known or suspected to influence outcome after THA, 
such as obesity, diabetes mellitus or other comorbidities, and 
intake of immunosuppressive or non-steroidal inflammatory 
drugs (Persson et al. 2005, Gilson et al. 2010, Bozic et al. 2012, 
Jamsen et al. 2012), were not registered in the database.
Strengths and limitations
The high number of THAs investigated was a strength in 
this study: 22 different uncemented stem brands in 4 differ-
ent countries were included, with 7 of the stems used in at 
least 3 participating countries. The stem brands investigated 
are in current use, whereas historical designs were not evalu-
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ated. Moreover, this large cohort allowed investigation of rare 
events such as stem revision due to aseptic loosening and due 
to infection. We therefore believe that our findings are rep-
resentative of THA patients. It should be noted that absence 
of statistically significant differences between HA-coated 
and non-HA-coated stems is not necessarily evidence of their 
absence, but failure to detect statistically significant differ-
ences in this large material indicates that the clinical relevance 
of such putative differences is questionable.
One strength of the study was that we analyzed a large 
number of uncoated and HA-coated versions of the Bimet-
ric prosthesis. A weakness of this comparison is that both the 
collared and the collarless versions of this stem brand were 
summarized under the term Bimetric, but subgrouping would 
have further reduced the available numbers of observations 
and events and inflated estimation uncertainty. On the other 
hand, no previous studies have indicated that there is any 
difference in survival between the 2 different stem variants. 
Other prostheses available both with and without HA coating 
(Filler, Profemur, and CLS) had not been used in sufficient 
numbers to allow valid comparisons, given the low number of 
stem revisions relative to the total number of procedures.
Limitations concerning completeness and coverage are 
inherent in observational studies based on registry materials. 
The NARA collaboration receives data from Denmark, Fin-
land, Norway, and Sweden, and the respective registries have 
been repeatedly validated. The completeness of data in the 4 
countries varies between 86% and 99% (Bergh et al. 2014). 
We tried to limit selection bias by only including stems that 
had been inserted at least 500 times in each participating 
country, thus avoiding bias introduced from low numbers of 
stems with either very good or very poor performance. Both 
high- and low-volume units were included in the analyses 
(data not shown), and this could have introduced bias if cer-
tain stems had predominated in one type of unit. However, we 
found no evidence that any of the stems investigated had been 
in used predominantly in units with either very high or very 
low volumes (data not shown). Detailed information on bear-
ing surfaces is not available in the NARA database, which is a 
weakness of the study.
Conclusion
Excellent long-term survival can be found for both HA-coated 
and non-HA-coated stems, and for one specific stem brand 
that was available with and without HA coating, this surface 
treatment had no certain influence on the risk of stem revision. 
We therefore believe that HA coating of stem components is 
not associated with clinically relevant effects on the survival 
of THA stems, and we question the use of HA coatings on 
well-functioning stems.
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